Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsAnshu K. Jain, MD
Assistant Clinical ProfessorAbout
Copy Link
Titles
Assistant Clinical Professor of Therapeutic Radiology
Education & Training
- Resident
- Columbia University College of Physicians and Surgeons (2014)
- Resident
- Massachusetts General Hospital (2010)
- MD
- University of Kentucky College of Medicine (2009)
- BA
- Duke University (2003)
Research
Copy Link
Research at a Glance
Publications Timeline
A big-picture view of Anshu K. Jain's research output by year.
14Publications
346Citations
Publications
2024
New Federal Guidance Makes It Harder for Patients With Cancer to Access Drugs
Mullangi S, Jain A, Wilfong L, Schleicher S. New Federal Guidance Makes It Harder for Patients With Cancer to Access Drugs. JCO Oncology Practice 2024, 20: 610-613. PMID: 38290088, DOI: 10.1200/op.23.00691.Peer-Reviewed Original ResearchAltmetric
2019
Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer
Anderson C, Lee C, Saunders D, Curtis A, Dunlap N, Nangia C, Lee A, Gordon S, Kovoor P, Arevalo-Araujo R, Bar-Ad V, Peddada A, Colvett K, Miller D, Jain A, Wheeler J, Blakaj D, Bonomi M, Agarwala S, Garg M, Worden F, Holmlund J, Brill J, Downs M, Sonis S, Katz S, Buatti J. Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer. Journal Of Clinical Oncology 2019, 37: 3256-3265. PMID: 31618127, PMCID: PMC6881100, DOI: 10.1200/jco.19.01507.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsChemoradiotherapyChemoradiotherapy, AdjuvantCisplatinDouble-Blind MethodFemaleHumansIncidenceMaleMiddle AgedMouth NeoplasmsOntarioOrganometallic CompoundsOropharyngeal NeoplasmsRadiation InjuriesRadiation-Protective AgentsRadiotherapy, Intensity-ModulatedRisk FactorsSeverity of Illness IndexStomatitisTime FactorsTreatment OutcomeUnited StatesConceptsDouble-blind trialOral mucositisRadiation therapyCancer Institute Common Terminology Criteria for Adverse EventsNational Cancer Institute Common Terminology Criteria for Adverse EventsPhase IIbCommon Terminology Criteria for Adverse EventsLocally advanced oral cavityPostoperative intensity-modulated RTToxicity of radiation therapyHead and neck cancerGrades of OMIntensity-modulated RTSevere oral mucositisAdverse events gradePhase III trialsAdvanced oral cavityActive dose levelsClinically meaningful reductionsConcurrent radiotherapyIMRT fractionsSevere OMDebilitating toxicityOropharynx cancerTumor characteristics
2016
Moving Toward Improved Teamwork in Cancer Care: The Role of Psychological Safety in Team Communication
Jain AK, Fennell ML, Chagpar AB, Connolly HK, Nembhard IM. Moving Toward Improved Teamwork in Cancer Care: The Role of Psychological Safety in Team Communication. JCO Oncology Practice 2016, 12: 1000-1011. PMID: 27756800, DOI: 10.1200/jop.2016.013300.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPsychological safetyCancer careLeader behaviorsTeam researchHigh-quality communicationTeam membersStatus differencesValue-based cancer careTeam communicationEarly-stage breast cancerFuture researchCommunication effectsCancer care deliveryBoundary spanningTeamworkEffective communicationBreast cancerCare providersClinical careCare deliveryTreatment planning processCarePatientsCommunicationFamiliarityCentromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy
Zhang W, Mao JH, Zhu W, Jain AK, Liu K, Brown JB, Karpen GH. Centromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy. Nature Communications 2016, 7: 12619. PMID: 27577169, PMCID: PMC5013662, DOI: 10.1038/ncomms12619.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords
2014
The role of stereotactic body radiotherapy and stereotactic radiosurgery in the re-irradiation of metastatic spinal tumors.
Jain AK, Yamada YJ. The role of stereotactic body radiotherapy and stereotactic radiosurgery in the re-irradiation of metastatic spinal tumors. Expert Review Of Anticancer Therapy 2014, 14: 1141-52. PMID: 25066490, DOI: 10.1586/14737140.2014.940326.Peer-Reviewed Original Research
2012
Adjuvant strategies for resectable pancreatic cancer: have we made progress?
Russo S, Jain AK, Saif MW. Adjuvant strategies for resectable pancreatic cancer: have we made progress? JOP : Journal Of The Pancreas 2012, 13: 139-42. PMID: 22406585.Peer-Reviewed Original Research
2011
Intensity-modulated radiotherapy for locally advanced cancers of the larynx and hypopharynx.
Daly ME, Le QT, Jain AK, Maxim PG, Hsu A, Loo BW, Kaplan MJ, Fischbein NJ, Colevas AD, Pinto H, Chang DT. Intensity-modulated radiotherapy for locally advanced cancers of the larynx and hypopharynx. Head & Neck 2011, 33: 103-11. PMID: 20848427, DOI: 10.1002/hed.21406.Peer-Reviewed Original Research
2010
High-performance teams and the physician leader: an overview.
Majmudar A, Jain AK, Chaudry J, Schwartz RW. High-performance teams and the physician leader: an overview. Journal Of Surgical Education 2010, 67: 205-9. PMID: 20816354, DOI: 10.1016/j.jsurg.2010.06.002.Peer-Reviewed Original Research
2009
A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC).
Jain AK, Hughes RS, Sandler AB, Dowlati A, Schwartzberg LS, Dobbs T, Schlabach L, Wu J, Muldowney NJ, Choy H. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC). Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2009, 4: 722-7. PMID: 19404213, DOI: 10.1097/JTO.0b013e3181a5275c.Peer-Reviewed Original ResearchRTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer.
Choy H, Jain AK, Moughan J, Curran W, Whipple G, Demas WF, Ettinger DS. RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2009, 4: 80-6. PMID: 19096311, DOI: 10.1097/JTO.0b013e318191503f.Peer-Reviewed Original Research